TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04230252
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
Study: NCT03564379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet will be administered orally.
Study: NCT02986659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00571558
Drug: aminolevulinic acid hydrochloride
Normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00571558
Drug: photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo photodynamic therapy
Study: NCT01107106
Drug: ellaOne® (ulipristal acetate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one single oral dose (30 mg tablet)
Study: NCT00540384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00733577
Drug: SB756050
Approvals — FDA: no, EMA: no, PMDA: no
Description: doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
Study: NCT00132951
Drug: Telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin (AECB: 2 tablets per day for Days 1-5; CAP: 2 tablets per day for Days 1-7)
Study: NCT00132951
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AECB: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5; CAP: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5 then 2 placebo tablets per day for Days 6-7)
Study: NCT00447629
Drug: PPM-204
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00978497
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral BID
Study: NCT00978497
Drug: ANA598
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral 400mg BID
Study: NCT00000578
Drug: theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01093170
Drug: RNA-144101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreous administration of RNA-144101
Study: NCT02512861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients \> 50 kgs
Study: NCT04335591
Drug: Placebo capsule to match Add-back capsule
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral administration once daily
Study: NCT03498131
Drug: 3 mg Melatonin
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 mg melatonin once each day
Study: NCT03498131
Drug: 5 mg Melatonin
Normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg Melatonin once each day
Study: NCT03730311
Drug: Elpida
Approvals — FDA: no, EMA: no, PMDA: no
Description: elsulfavirine, capsules
Study: NCT03730311
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04394234
Drug: Direct oral anticoagulant (DOACs)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data of participants newly exposed to individual DOACs that is rivaroxaban, apixaban, dabigatran from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
Study: NCT00922441
Drug: Reference (Valsartan 80 mg) group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference (Valsartan 80 mg)
Study: NCT01887990
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline infusion
Study: NCT03248713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sugar 2 tablets will be compared to mifepristone
Study: NCT01359878
Drug: Isotonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline in equivalent volume - 100 ml
Study: NCT02188277
Drug: Botox®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
Study: NCT02242799
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
Study: NCT02798913
Drug: Long DAPT
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
Study: NCT03405441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive matching placebo orally in Part 1 and Part 2 of the study.
Study: NCT03690921
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01525641
Drug: Mirapex LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole Hydrochloride Hydrate
Study: NCT00735462
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied daily to wart areas for up to 8 weeks
Study: NCT02236598
Drug: K+ supplement
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02236598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03220165
Drug: MGL-3196
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, 100 mg
Study: NCT00945763
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT04097691
Drug: GLUCOSE 10%
Normalized name: glucose 10% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous glucose 0.5 ml per site around subcutaneous nerves
Study: NCT04853407
Drug: LY03005 extended-release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally once a day
Study: NCT04853407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally once a day
Study: NCT00510263
Drug: Prednisolone + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
Study: NCT00510263
Drug: Placebo + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
Study: NCT00993018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive single injection of matching placebo every 28 days for up to 52 weeks.
Study: NCT04161547
Drug: CSPCHA115 100 mg; Matching placebo 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.
Study: NCT04161547
Drug: CSPCHA115 200 mg; Matching placebo 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.
Study: NCT04161547
Drug: CSPCHA115 400 mg; Matching placebo 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.
Study: NCT04161547
Drug: CSPCHA115 600 mg; Matching placebo 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.
Study: NCT02213926
Drug: ACP-196 (acalabrutinib)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00836914
Drug: CAL-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
Study: NCT00836914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules administered orally BID for 7 days
Study: NCT03284593
Drug: intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00804414
Drug: SBG
Normalized name: PSBG - Pregnancy specific beta 1-glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for topical use
Study: NCT00804414
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solutin for topical use
Study: NCT02057302
Drug: Xuezhikang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01196104
Drug: Technosphere® Insulin Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01720797
Drug: Anesthestic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.
Study: NCT01654822
Drug: topical application cervical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
Study: NCT00585559
Drug: Placebos for acetaminophen and N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos for acetaminophen and N-acetylcysteine
Study: NCT00585559
Drug: APAP 1 gm every 6 hours and N-acetylcysteine placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
Study: NCT00585559
Drug: NAC IV infusion at 0.5 gm hourly and APAP placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
Study: NCT00585559
Drug: APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
Study: NCT03852160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo as nasal spray.
Study: NCT00585559
Drug: APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
Study: NCT00264472
Drug: ADH300004
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg
Study: NCT06027775
Drug: Targeted agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: The two cohorts received different adjuvant therapy regimens, with the CT group receiving chemotherapy plus targeted therapy; the CA group received chemotherapy alone.
Study: NCT03814746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for infusion IV.
Study: NCT01723514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection once a month
Study: NCT04310176
Drug: mFOLFOX6 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 followed by levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two week
Study: NCT04310176
Drug: mOXXEL regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 plus oral capecitabine 1000 mg/m2 twice daily on days 1 to 10, every 2 weeks
Study: NCT04310176
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maintenance treatment (both arms): 1250 mg/m2 twice daily on days 1 to 14, every 3 weeks or 1250 mg/m2 twice daily on days 1 to 10, every 2 weeks
Study: NCT00979745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 16mg subcutaneous implant every 2 months for 9 months.
Study: NCT03657537
Drug: Ketone infusion
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-hydroxybutyrate is infused intravenously.
Study: NCT03657537
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline is infused intravenously.
Study: NCT03709316
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Study: NCT01845558
Drug: Wobenzym® plus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01747629
Drug: Placebo MDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
Study: NCT03199300
Drug: Anthracyclines
Normalized name: Anthracyclines and related substances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen containing anthracyclines.
Study: NCT01544309
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.~(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin \[RSV\] dose of 10 mg.)
Study: NCT00741351
Drug: Sevoflurane + Fentanyl
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
Study: NCT00741351
Drug: Sevoflurane + Remifentanyl
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
Study: NCT00741351
Drug: Propofol + Remifentanyl
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
Study: NCT01544491
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
Study: NCT00780442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03961347
Drug: L. johnsonii Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
Study: NCT03961347
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
Study: NCT00570258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 150 mg PO QD
Study: NCT00181532
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01196247
Drug: Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA approved drugs as indicated by molecular profiling
Study: NCT00291863
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04459117
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II.
Study: NCT03716583
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg
Study: NCT04656652
Drug: DS-1062a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1062a will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
Study: NCT03716583
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g
Study: NCT01102387
Drug: LAS41003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, topically
Study: NCT01102387
Drug: LAS189962
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, topically
Study: NCT01102387
Drug: LAS189961
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, topically
Study: NCT01114698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 2 capsules identical in appearance to JNJ26489112 and venlafaxine XR orally administered once daily for 6 weeks.
Study: NCT01114698
Drug: JNJ26489112
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ26489112 500 mg/day orally administered once daily as 2 capsules for the first 3 weeks, then dose may be increased to 1000 mg/day by week 4.
Study: NCT04266093
Drug: GeneTherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation/ Gene Therapy Long-term Follow-up. Subjects who have enrolled on an applicable NCI CIO gene therapy treatment protocol.
Study: NCT00657475
Drug: Heparin Low Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.
Study: NCT00657475
Drug: Heparin Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
Study: NCT03439345
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
Study: NCT04137302
Drug: Hydrocortisone administration
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments
Study: NCT01586533
Drug: Zoenasa-1:4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoenasa Rectal Gel (4.0g mesalamine \[5-ASA\], 1.0g N-acetylcysteine \[NAC\]; 60ml)
Study: NCT01586533
Drug: Mesalamine Enema
Normalized name: mesalamine Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine Rectal Suspension Enema (4.0g mesalamine \[5-ASA\], 60ml)
Study: NCT00729053
Drug: IMO-2055
Approvals — FDA: no, EMA: no, PMDA: no
Description: immunostimulatory oligonucleotide
Study: NCT02306161
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02306161
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02306161
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00945178
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, single oral dose, 500mg
Study: NCT04606381
Drug: Ami-HC-CF
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.
Study: NCT03300609
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03300609
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03300609
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03698630
Drug: Prednisolone Sodium Phosphate
Normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednesol 5mg Tablets (Phoenix Labs Ltd). Pink, circular, flat, bevel-edged scored tablets containing 5 mg of prednisolone as prednisolone sodium phosphate.
Study: NCT04200404
Drug: CS1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: One course will last 28 days. CS1001 will be intravenously administered every 4 weeks (Q4W).
Study: NCT00848393
Drug: Fentanyl (High Dose)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl (High Dose) 25 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
Study: NCT00848393
Drug: Fentanyl (Low Dose)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl (Low Dose) 10 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
Study: NCT00848393
Drug: Fentanyl (Low Dose) + Dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (Low Dose) + Dexmedetomidine. Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr. In addition, this group will receive a total of 10 mcg/kg Fentanyl (Low Dose). Half the dose will be given at induction and the second half before incision.
Study: NCT01935596
Drug: ropivacaïne
Approvals — FDA: no, EMA: no, PMDA: no
Description: spinal anesthesia.
Study: NCT01935596
Drug: lévobupivacaïne
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01750086
Drug: Alendronate Oral Tablet
Normalized name: alendronate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly alendronate for 8 weeks
Study: NCT00003133
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04252300
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of 5 mg rosuvastatin is administered as tablet orally on Day 1 of Period 1 (total length = 5 days).